ABSTRACT
Baseline lung function, quantified as forced expiratory volume in the first second of exhalation (FEV1), is a standard diagnostic criterion used by clinicians to identify and classify lung diseases. Using whole genome sequencing data from the National Heart, Lung, and Blood Institute TOPMed project, we identified a novel genetic association with FEV1 on chromosome 12 in 867 African American children with asthma (p = 1.26 × 10−8, β = 0.302). Conditional analysis within 1 Mb of the tag signal (rs73429450) yielded one major and two other weaker independent signals within this peak. We explored statistical and functional evidence for all variants in linkage disequilibrium with the three independent signals and yielded 9 variants as the most likely candidates responsible for the association with FEV1. Hi-C data and eQTL analysis demonstrated that these variants physically interacted with KITLG (aka SCF) and their minor alleles were associated with increased expression of KITLG gene in nasal epithelial cells. Gene-by-air-pollution interaction analysis found that the candidate variant rs58475486 interacted with past-year SO2 exposure (p = 0.003, β = 0.32). This study identified a novel protective genetic association with FEV1, possibly mediated through KITLG, in African American children with asthma.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Genes-Environments and Admixture in Latino Americans (GALA II) Study, the Study of African Americans, Asthma, Genes and Environments (SAGE) Study and E.G.B. were supported by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, the Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute (NHLBI) [R01HL117004, R01HL128439, R01HL135156, X01HL134589]; the National Institute of Environmental Health Sciences [R01ES015794]; the National Institute on Minority Health and Health Disparities (NIMHD) [P60MD006902, R01MD010443], the National Human Genome Research Institute [U01HG009080] and the Tobacco-Related Disease Research Program [24RT-0025]. MJW was supported by the NHLBI [K01HL140218]. JJ and BEH were supported by the NHLBI [R01HL133433, R01HL141992]. KLK was supported by the NHLBI [R01HL135156-S1], the UCSF Bakar Institute, the Gordon and Betty Moore Foundation [GBMF3834], and the Alfred P. Sloan Foundation [2013-10-27] grant to UC Berkeley through the Moore-Sloan Data Science Environment Initiative. ACW was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development [1R01HD085993-01]. The SAPPHIRE study was supported by the Fund for Henry Ford Hospital, the American Asthma Foundation, the NHLBI [R01HL118267, R01HL141485, X01HL134589], the National Institute of Allergy and Infectious Diseases [R01AI079139], and the National Institute of Diabetes and Digestive and Kidney Diseases [R01DK113003]. The GCPD-A study was supported by an Institutional award from the Children’s Hospital of Philadelphia and by the NHLBI [X01HL134589]. Part of this research was conducted using the UK Biobank Resource under Application Number 40375. We would like to thank UK Biobank participants and researchers who contributed or collected data. Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). WGS for "NHLBI TOPMed: Gene-Environment, Admixture and Latino Asthmatics Study" (phs000920) and "NHLBI TOPMed: Study of African Americans, Asthma, Genes and Environments" (phs000921) was performed at the New York Genome Center (3R01HL117004-02S3) and the University of Washington Northwest Genomics Center (HHSN268201600032I). WGS for "NHLBI TOPMed: Study of Asthma Phenotypes & Pharmacogenomic Interactions by Race-Ethnicity" (phs001467) and “Genetics of Complex Pediatric Disorders - Asthma” (phs001661) was performed at the University of Washington Northwest Genomics Center (HHSN268201600032I). Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Phenotype harmonization, data management, sample-identity QC, and general study coordination were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1; contract HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed. WGS of part of GALA II was performed by New York Genome Center under The Centers for Common Disease Genomics of the Genome Sequencing Program (GSP) Grant (UM1 HG008901). The GSP Coordinating Center (U24 HG008956) contributed to cross-program scientific initiatives and provided logistical and general study coordination. GSP is funded by the National Human Genome Research Institute, the National Heart, Lung, and Blood Institute, and the National Eye Institute. The TOPMed imputation panel was supported by the NHLBI and TOPMed study investigators who contributed data to the reference panel. The panel was constructed and implemented by the TOPMed Informatics Research Center at the University of Michigan (3R01HL-117626-02S1; contract HHSN268201800002I). The TOPMed Data Coordinating Center (3R01HL-120393-02S1; contract HHSN268201800001I) provided additional data management, sample identity checks, and overall program coordination and support. We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Local institutional review boards approved the studies (IRB# 10-02877). All subjects and legal guardians provided written informed consent. TOPMed whole genome sequencing and phenotype data from SAGE II are available on dbGaP under accession number phs000921.v4.p1. Normalized gene count data for KITLG and supplemental materials are available at figshare.
